Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

被引：0

作者：

Keller, Anne-Valerie ^{[1
]}

Hajiyianni, Marina ^{[2
]}

Kurre, Eileen ^{[1
]}

Mai, Elias Karl ^{[1
,2
]}

Bertsch, Uta ^{[1
,2
,3
]}

Benner, Axel ^{[4
]}

Luntz, Steffen ^{[5
]}

Raab, Marc-Steffen ^{[1
,2
]}

Besemer, Britta ^{[6
]}

Michel, Christian Sebastian ^{[7
]}

Schroers, Roland ^{[8
]}

Fenk, Roland ^{[9
]}

Salwender, Hans ^{[10
]}

Blau, Igor Wolfgang ^{[11
]}

Haenel, Mathias ^{[2
,12
]}

Mann, Christoph ^{[13
]}

Goldschmidt, Hartmut ^{[1
,2
,3
]}

机构：

[1] Heidelberg Univ Hosp, Internal Med Hematol Oncol & Rheumatol 5, GMMG Study Grp, Heidelberg, Germany

[2] Univ Hosp Heidelberg, Heidelberg Myeloma Ctr, Dept Med 5, Heidelberg, Germany

[3] Natl Ctr Tumor Dis Heidelberg, Heidelberg, Germany

[4] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[5] Coordinat Ctr Clin Trials KKS, Heidelberg, Germany

[6] Univ Hosp Tubingen, Dept Internal Med 2, Tubingen, Germany

[7] Univ Hosp Mainz, Dept Internal Med 3, Mainz, Germany

[8] Univ Hosp Bochum, Med Clin, Bochum, Germany

[9] Univ Hosp Dusseldorf, Dept Haematol Oncol & Clin Immunol, Dusseldorf, Germany

[10] Asklepios Hosp Hamburg Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[11] Med Klin M S Hamatol Onkol & Tumorimmunol, Berlin, Germany

[12] Klinikum Chemnitz, Dept Internal Med 3, Chemnitz, Germany

[13] Philipps Univ Marburg, Dept Hematol Oncol & Immunol, Marburg, Germany

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-194188

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：5140 / 5142

页数：3

共 50 条

[1] Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
Goldschmidt, Hartmut
Mai, Elias K.
Bertsch, Uta
Besemer, Britta
Haenel, Mathias
Miah, Kaya
Fenk, Roland
Schlenzka, Jana
Munder, Markus
Duerig, Jan
Blau, Igor Wolfgang
Huhn, Stefanie
Hose, Dirk
Jauch, Anna
Kunz, Christina
Neubauer, Andreas
Scheid, Christof
Schroers, Roland
von Metzler, Ivana
Schieferdecker, Aneta
Thomalla, Joerg
Reimer, Peter
Mahlberg, Rolf
Graeven, Ullrich
Kremers, Stephan
Martens, Uwe M.
Kunz, Christian
Hensel, Manfred
Seidel-Glaetzer, Andrea
Weisel, Katja
Raab, Marc-Steffen
Salwender, Hans
BLOOD, 2021, 138
[2] Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Salwender, Hans-Juergen
Van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Blau, Igor W.
Zweegman, Sonja
Weisel, Katja C.
Vellenga, Edo
Pfreundschuh, Michael
Broijl, Annemiek
Scheid, Christof
Wittebol, Shulamiet
Bos, Gerard M. J.
Stevens-Kroef, Marjan
Jauch, Anna
Potamianou, Anna
Hose, Dirk
Raymakers, Reinier
Schaafsme, Marinus
Kersten, Marie Jose
Kooy, Marinus van Marwijk
Duehrsen, Ulrich
Lindemann, Hans Walter
Brossart, Peter
Wijermans, Pierre
Lokhorst, Henk M.
Goldschmidt, Hartmut
BLOOD, 2015, 126 (23)
[3] Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Salwender, Hans
Elmaagacli, Ahmet
Merz, Maximilian
Miah, Kaya
Benner, Axel
Haenel, Mathias
Jehn, Christian
Mai, Elias K.
Bertsch, Uta
Blau, Igor W.
Scheid, Christof
Hose, Dirk
Seckinger, Anja
Jauch, Anna
Raab, Marc S.
Luntz, Steffen P.
Besemer, Britta
Munder, Markus
Brossart, Peter
Fuhrmann, Stephan
Lindemann, Hans-Walter
Weisel, Katja
Duerig, Jan
Goldschmidt, Hartmut
LEUKEMIA, 2021, 35 (10) : 3007 - 3011
[4] Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender
Ahmet Elmaagacli
Maximilian Merz
Kaya Miah
Axel Benner
Mathias Haenel
Christian Jehn
Elias K. Mai
Uta Bertsch
Igor W. Blau
Christof Scheid
Dirk Hose
Anja Seckinger
Anna Jauch
Marc S. Raab
Steffen P. Luntz
Britta Besemer
Markus Munder
Peter Brossart
Stephan Fuhrmann
Hans-Walter Lindemann
Katja Weisel
Jan Duerig
Hartmut Goldschmidt
Leukemia, 2021, 35 : 3007 - 3011
[5] Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Scheid, Christof
van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Vellenga, Edo
Broyl, Annemiek
Blau, Igor Wolfgang
Weisel, Katja
Wittebol, Shulamit
Bos, Gerard M. J.
Stevens, Marjan
Schmidt-Wolf, Ingo G. H.
Pfreundschuh, Michael
Hose, Dirk
Jauch, Anna
van de Velde, Helgi
Raymakers, Reinier
Schaafsma, Martyn Ronald
Kersten, Marie Jose
Kooy, Marinus van Marwijk
Duehrsen, Ulrich
Lindemann, Hans Walter
Wijermans, Pierre W.
Lokhorst, Henk
Goldschmidt, H.
BLOOD, 2013, 122 (21)
[6] Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4
Mai, Elias Karl
Kunz, Christina
Bertsch, Uta
Salwender, Hans-Juergen
Pfreundschuh, Michael
Duehrsen, Ulrich
Brossart, Peter
Peter, Norma
Neben, Kai
Hielscher, Thomas
Hillengass, Jens
Martin, Hans
Lindemann, Hans Walter
Scheid, Christof
Weisel, Katja C.
Blau, Igor W.
Goldschmidt, Hartmut
BLOOD, 2015, 126 (23)
[7] Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
Mai, Elias K.
Nogai, Axel
Lokhorst, Henk M.
van der Holt, Bronno
Zweegman, Sonja
Weisel, Katja C.
Croockewit, Sandra
Jauch, Anna
Hillengass, Jens
Stevens-Kroef, Marian
Raab, Marc S.
Broijl, Annemiek
Bos, Gerard M. J.
Brossart, Peter
Ypma, Paula
Hanoun, Christine
Bertsch, Uta
Hielscher, Thomas
Salwender, Hans J.
Scheid, Christoph
Goldschmidt, Hartmut
Sonneveld, Pieter
HEMASPHERE, 2024, 8 (11):
[8] Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Schmidt-Wolf, Ingo G. H.
van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Vellenga, Edo
Broyl, Annemiek
Blau, Igor W.
Weisel, Katja C.
Wittebol, Shulamiet
Bos, Gerard M. J.
Stevens-Kroef, Marian
Scheid, Christof
Pfreundschuh, Michael
Hose, Dirk
Jauch, Anna
van der Velde, Helgi
Raymakers, Reinier
Schaafsma, Martijn R.
Kersten, Marie-Jose
van Marwijk-Kooy, Marinus
Duehrsen, Ulrich
Lindemann, Walter
Wijermans, Pierre W.
Lokhorst, Henk M.
Goldschmidt, Hartmut M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 2946 - 2955
[9] CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Kriegsmann, Katharina
Ton, Gigi Nu Hoang Quy
Awwad, Mohamed H. S.
Benner, Axel
Bertsch, Uta
Besemer, Britta
Haenel, Mathias
Fenk, Roland
Munder, Markus
Duerig, Jan
Blau, Igor W.
Huhn, Stefanie
Hose, Dirk
Jauch, Anna
Mann, Christoph
Weinhold, Niels
Scheid, Christof
Schroers, Roland
von Metzler, Ivana
Schieferdecker, Aneta
Thomalla, Joerg
Reimer, Peter
Mahlberg, Rolf
Graeven, Ullrich
Kremers, Stephan
Martens, Uwe M.
Kunz, Christian
Hensel, Manfred
Seidel-Glaetzer, Andrea
Weisel, Katja C.
Salwender, Hans J.
Mueller-Tidow, Carsten
Raab, Marc S.
Goldschmidt, Hartmut
Mai, Elias K.
Hundemer, Michael
LEUKEMIA, 2024, 38 (07) : 1621 - 1625
[10] Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Hans Salwender
Uta Bertsch
Katja Weisel
Jan Duerig
Christina Kunz
Axel Benner
Igor W. Blau
Marc Steffen Raab
Jens Hillengass
Dirk Hose
Stefanie Huhn
Michael Hundemer
Mindaugas Andrulis
Anna Jauch
Andrea Seidel-Glaetzer
Hans-Walter Lindemann
Manfred Hensel
Stefan Fronhoffs
Uwe Martens
Timon Hansen
Mohammed Wattad
Ullrich Graeven
Markus Munder
Roland Fenk
Mathias Haenel
Christof Scheid
Hartmut Goldschmidt
BMC Cancer, 19

← 1 2 3 4 5 →